@prefix biolink: .
@prefix ns1: .
@prefix this: .
@prefix sub: .
@prefix schema: .
@prefix np: .
@prefix dct: .
@prefix rdf: .
@prefix xsd: .
@prefix rdfs: .
@prefix orcid: .
@prefix prov: .
@prefix npx: .
sub:Head {
this: np:hasAssertion sub:assertion;
np:hasProvenance sub:provenance;
np:hasPublicationInfo sub:pubinfo;
a np:Nanopublication .
}
sub:assertion {
biolink:category biolink:Disease .
sub:association rdf:object ;
rdf:predicate biolink:treats;
rdf:subject ;
a rdf:Statement;
rdfs:label "\"Sumatriptan succinate tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( )] 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( )] 5.2 History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke ee [s Warnings and Precautions ( )] 5.4 Peripheral vascular disease [see Warnings and Precautions ( )] 5.5 Ischemic bowel disease [see Warnings and Precautions ( )] 5.5 Uncontrolled hypertension [see Warnings and Precautions ( )] 5.8 Recent use (i.e., within 24 hours) of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-hydroxytryptamine1 (5-HT ) agonist 1 [see Drug Interactions ( , )] 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor [see Drug Interactions ( ) and Clinical Pharmacology ( )] 7.2 12.3 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen) [see Warnings and Precautions ( )] 5.9 Severe hepatic impairment [see Use in Specific Populations ( ) and Clinical Pharmacology ( )] 8.6 12.3 History of coronary artery disease or coronary artery vasospasm ( ) 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( ) 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( ) 4 Peripheral vascular disease ( ) 4 Ischemic bowel disease ( ) Uncontrolled hypertension ( ) 4 4 Recent (within 24 hours) use of another 5-HT agonist (e.g., another triptan) or of an ergotamine-containing medication. ( ) 1 4 Concurrent or recent (past 2 weeks) use of monoamine oxidase-A inhibitor. ( ) 4 Hypersensitivity to sumatriptan succinate tablets (angioedema and anaphylaxis seen). ( ) 4 Severe hepatic impairment. ( ) 4\"";
biolink:provided_by ;
biolink:relation schema:MedicalContraindication .
biolink:category biolink:Drug .
}
sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}
sub:pubinfo {
sub:sig npx:hasAlgorithm "RSA";
npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB";
npx:hasSignature "ZAh6oE0xACbDNCRg2RfWCvcnyRv+XJ9vzKh/Z8eznwTvZCjS7JXJFpAEP8A7ODePRriXLqV/Zc6upMDwsM7tzbxbRvgW27IYpx3wVCiFAGnHpDPclL+rLI7CV86NUegqbA1UQUlQ0kyir50Al2MdibYTLgPbalvzxw4fcFWdnYs=";
npx:hasSignatureTarget this: .
this: dct:created "2021-08-23T13:06:35.109+02:00"^^xsd:dateTime;
dct:creator orcid:0000-0002-1468-3557;
ns1:wasCreatedFromProvenanceTemplate ;
ns1:wasCreatedFromPubinfoTemplate ;
ns1:wasCreatedFromTemplate .
}